| Abstrakt: |
A recent study conducted by researchers at Southwest Medical University in Sichuan, China, explores the potential applications of dual haptoglobin (HP) expression in the reclassification and treatment of hepatocellular carcinoma (HCC), a type of liver cancer. The study found that HP is highly expressed in HCC malignant cells and lowly expressed in T cells. Elevated HP expression in malignant cells promotes Th1-type immune responses, while down-regulating HP expression in T cells enhances Th1-type responses. The researchers developed a gene set that correlates higher HP activity scores with improved survival rates in HCC patients and established four predictive models for neoadjuvant treatment based on HP and C3 expression. This research provides insights for HCC patient survival prognosis and clinical treatments. [Extracted from the article] |
